沙立度胺对多发性骨髓瘤患者细胞因子影响的临床研究  

Clinical study of effects of thalidomide on cytokines in patients with multiple myeloma

作　　者：杨云[1] 张王刚[1] 陈银霞[1] 曹星梅[1] 何爱丽[1] 刘捷[1] 田玮[1] 

机构地区：[1]西安交通大学附属第二医院血液科,西安710004

出　　处：《临床血液学杂志》2007年第5期272-274,共3页Journal of Clinical Hematology

摘　　要：目的:探讨沙立度胺对多发性骨髓瘤(MM)患者几种细胞因子的免疫调节作用。方法:用ELISA方法检测沙立度胺治疗前后患者血清中干扰素-γ(IFN-γ)、白细胞介素(IL)-6、IL-10浓度的变化。结果:22例患者治疗前IFN-γ水平明显低于正常人(P<0.01),IL-6、IL-10水平明显高于正常人(均P<0.01);治疗后IFN-γ水平较治疗前无明显变化(P>0.05),12例治疗有效者的IL-6、IL-10水平较治疗前明显降低(P<0.01),10例治疗无效者的IL-6、IL-10水平较治疗前降低,但差异无统计学意义(P>0.05)。结论:通过降低MM患者血清中IL-6、IL-10水平可能是沙立度胺治疗MM有效的机制之一。Objective：To explore the immunoregulatory effects of thalidomide on several cytokines in patients with multiple myeloma（MM）. Method：ELISA was used to detect the concentrations of IFN-γ. IL-6、 IL-10 in serum of the MM patients before and after treatment. Result： Compared with the healthy volunteers, serum IFN-γ level decreased significantly （ P〈0.01）, and serum IL-6 and IL-10 levels increased significantly（ P 〈0.01） in twenty-two MM patients before treatment. Compared with before treatment, the changes of serum IFN-γ level was not significant after thalidomide treatment （ P〉0.05）. The serum concentrations of IL-6 and IL-10 in 12 patients of response decreased significantly（ P〈0.01）, but there was no significant decreases in ten patients of no response （ P〉0. 05）. Conclusion：Down-regulating IL-6, IL-10 in serum of MM patients was probably one of the mechanisms of action of thalidomide.

关 键 词：多发性骨髓瘤 沙立度胺 免疫调节 细胞因子 

分 类 号：R733.3[医药卫生—肿瘤]